Week ending July 14, 2017
H.R.1492 – Medical Controlled Substances Transportation Act of 2017
“The Controlled substance Act currently prohibits the transportation and administration of controlled substances away from the location registered with DEA. Therefore, the statute does not permit registered practitioners with inherently mobile practices, such as emergency medical services personnel traveling to a disaster area, to transport and administer pain or anti-seizure medication.”
The bill, then, ‘would amend the Controlled Substances Act (CSA) to authorize a practitioner, who is registered under section 303(f) of the CSA, to transport and administer controlled substances to patients outside of the State in which they are registered under subsection (f) at locations other than a principal place of business or professional practice. In order to do so, the practitioner would need to have a separate registration issued by the Drug Enforcement Administration (DEA) pursuant to section 303(k), as added by this bill, and meet a number of conditions.’ Bill report.
(Full text of H.R. 1492 at congress.gov)
Sponsor: Rep. Sessions, Pete [R-TX-32] (Introduced 03/10/2017)
Status: Passed House /
VOTES and FLOOR ACTION
On Passage: On motion to suspend the rules and pass the bill Agreed to by the Yeas and Nays: (2/3 required): 416 – 2 (Roll no. 349).
Motion to recommit:
Text of the motion:
COST AND IMPACT
Cost to the taxpayers: Data not available
Pay-as-you-go requirements: Data not available
Regulatory and Other Impact: None
Dynamic Scoring: Data not available
Tax Complexity: Not applicable to this bill.
Earmark Certification: None
Duplication of programs: None
Direct Rule-Making: None
Advisory Committee Statement: Data not available
Budget Authority: Data not available
Constitutional Authority: Assumed.
More Bill Information:
Copyright 2017 Legislation News & Report, LLC
All Rights Reserved